EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Moberg Pharma AB's Enterprise Value is €20.29 Mil.
Moberg Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.08 Mil. Therefore, Moberg Pharma AB's EV-to-FCF for today is -4.97.
The historical rank and industry rank for Moberg Pharma AB's EV-to-FCF or its related term are showing as below:
FRA:MB8'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.61 Med: -1.28 Max: 352.83
Current: -4.97
During the past 13 years, the highest EV-to-FCF of Moberg Pharma AB was 352.83. The lowest was -12.61. And the median was -1.28.
FRA:MB8's EV-to-FCF is ranked worse than 100% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs FRA:MB8: -4.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Moberg Pharma AB's PE Ratio (TTM) for today is calculated as:
Moberg Pharma AB's share price for today is €0.80.
Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Moberg Pharma AB EV-to-FCF Related Terms
Moberg Pharma AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's EV-to-FCF falls into.
Moberg Pharma AB's current Enterprise Value is €20.29 Mil.
Moberg Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (FRA:MB8) has a EV-to-FCF of -4.97 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Moberg Pharma AB and its competitors. According to the industry distribution chart, Moberg Pharma AB ranks #999999 out of 558 companies in the Drug Manufacturers industry.
Is Moberg Pharma AB's EV-to-FCF too high?
Moberg Pharma AB's current EV-to-FCF is -4.97. Based on the distribution chart, Moberg Pharma AB ranks #999999 out of 558 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #999999 out of 558 companies for EV-to-FCF. This places Moberg Pharma AB in the lower half of its industry. The industry median EV-to-FCF is 20.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current EV-to-FCF is -4.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current EV-to-FCF of -4.97. The stock's GF Value™ is €1.07, compared to a current price of €0.80 — trading 25.2% below its estimated fair value. The current EV-to-FCF is -4.97. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current EV-to-FCF is -4.97 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.80 is trading 25.2% below its estimated GF Value™ of €1.07.
Key valuation signals for FRA:MB8:
EV-to-FCF: -4.97
GF Value™: €1.07 vs. price of €0.80 (25.2% below fair value)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
